Journals / Marmara Medical Journal / 2009 / Cilt: 22 - Sayı: 3

Prognostic value of immunohistochemical expression of vegf, e- cadherin and bim in radical prostatectomy specimens

Radikal prostatektomi spesmenlerindeki vegf’in, e-cadherin’in ve bım’in immünohistokimyasal ekspresyonlarının prognostik değeri

Pages
203–216
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These biomarkers should be studied in larger series of patients and immunohistochemical staining could be examined with quantitative image analysis method.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to evaluate the expressions of vascular endothelial growth factor (VEGF), E-Cadherin and Bim in radical prostatectomy specimens and to assess their prognostic value.
📊
Key Findings & Data:Materials and Methods: Sixty-six radical prostatectomy specimens from prostate cancer (51 stage pT2, 13 pT3, 2 pT4) were stained using VEGF, E-cadherin and Bim antibody.
💡
Conclusion & Impact:These biomarkers should be studied in larger series of patients and immunohistochemical staining could be examined with quantitative image analysis method.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to evaluate the expressions of vascular endothelial growth factor (VEGF), E-Cadherin and Bim in radical prostatectomy specimens and to assess their prognostic value. Materials and Methods: Sixty-six radical prostatectomy specimens from prostate cancer (51 stage pT2, 13 pT3, 2 pT4) were stained using VEGF, E-cadherin and Bim antibody. The correlations of VEGF, E-Cadherin and Bim immunoreactivity levels with Gleason scores and biochemical recurrence were examined. A statistical analysis was then performed according to the immunohistochemical and clinical data. Results: Patients were grouped according to the Gleason score (Gleason score <7 and Gleason &#8805;7) and biochemical recurrence (Prostate specific antigen (PSA)>0.2 ng/ml). Although there were insignificant differences in the expressions of VEGF, E-Cadherin and Bim in these groups, the expressions of VEGF were 59.74% in patients with biochemical recurrence and 44.47% in patients without biochemical recurrence (p=0,058). In a Spearman correlation test, there was a significant correlation between expressions of VEGF and E-Cadherin (p=0.05). Conclusion: We currently have no useful biomarker for the early identification of high risk patients and for deciding on treatment. These biomarkers should be studied in larger series of patients and immunohistochemical staining could be examined with quantitative image analysis method.

Özet

Giriş: Bu çalışmanın amacı radikal prostatektomi spesmenlerindeki vasküler büyüme faktörü (VEGF), E Cadherin ve Bim ekspresyonlarını değerlendirmek ve prognoz üzerine etkisini araştırmaktır. Gereç ve Yöntem: Radikal prostatektomi uygulanan 66 hastanın (51 hasta pT2, 13 hasta pT3, 2 hasta pT4 spesmenleri VEGF, E-Cadherin ve Bim antikorları ile boyandı. VEGF, E-Cadherin ve Bim immünoreaktivit sonuçlarının Gleason skoru ve biyokimyasal nüks ile olan ilişkileri araştırıldı. İmmünohistokimyasal v klinik verilere göre istatistiksel analiz yapıldı. Bulgular: Hastalar Gleason skoruna (Gleason score 0,2 ng/ml) göre gruplara ayrıldı. Gruplar arasında VEGF, E-Cadherin ve Bim ekspresyonlarında anlamlı fark olmamasına rağmen, biyokimyasal nüks saptanan hastalarda VEG ekspresyonu %59,74 ve biyokimyasal nüks saptanmayan hastalarda %44,47 bulundu (p=0,058). Spearma korelasyon testi uygulandığında, VEGF ve E-Cadherin arasında anlamlı bir ilişki tespit edildi (p=0,05). Sonuç: Tedaviye karar aşamasında yüksek riskli hasta grubunun belirlenmesinde kullanılabilece biyobelirteçe henüz sahip değiliz. Düşüncemiz daha büyük sayılı çalışmalarda bu biyobelirteçleri araştırılması ve immünohistokimyasal değerlendirmede imaj analiz yönteminin kullanılmasıdır.

🔖

Cite This Article

BAŞOK, E. K., YILDIRIM, A., BAŞARAN, A., ZEMHERİ, E., TOKUÇ, R. (2009). Prognostic value of immunohistochemical expression of vegf, e- cadherin and bim in radical prostatectomy specimens. Marmara Medical Journal, Cilt: 22 - Sayı: 3, 203–216. https://ajindex.com/articles/284069

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166
  2. Terakawa T, Miyake H, Kanomata N, et al. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL. Urology 2008; 72: 1194-1197
  3. Acar C, Sözen S, Erdem Ö, ve ark. Prostat kanserinde mikrodamar yoğunluğu, Kİ-67 ve p53 ekspresyonu ile klinikopatolojik ölçütler ve hasta prognozu arasındaki ilişki. Türk Üroloji Dergisi 2006; 32: 478-485
  4. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-1451
  5. Him HH, Cho SY, Park DS, et al. Prognostic factors of biochemical recurrence after radical prostatectomy in Korean men with high-risk prostate cancer. EJSO, article in press
  6. Eskiçorapçı SY. Prostat kanseri doğal seyri, prognostik faktörler ve nomogramlar. In:Özen H, Türkeri L, eds. Üroonkoloji Kitabı. Üroonkoloji Derneği; Ankara, Ertem Basım Yayın, 2007. 593-603
  7. Klagsbrun M, D�Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growt Factor Rev 1996; 7: 259-270
  8. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039
  9. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25
  10. Shibue T, Taniguchi T. BH3-only proteins: integrated control points of apoptosis. Int J Cancer 2006; 119: 2036-2043
  11. Yee KS, Vousden KH. Complicating the complexity of p53. Carcinogenesis 2005; 26: 1317-1322
  12. Chipuk JE, Bouchier-Hayes L, Kuwana T, et al. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005; 309: 1732-1735
  13. Mungan MU, Gurel D, Canda AE, ve ark. Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia, and renal cell carcinoma. Eur Urol 2006; 50: 92-97
  14. Noldus J, Graefen M, Haese A, et al. Stage migration in clinically localized prostate cancer. Eur Urol 2000; 38: 74-78
  15. Nicholson B, Theoderescu D. Angiogenesis and prostate cancer tumor growth, J Cell Biochem 2004; 91: 125-150
  16. Claffey KP, Brown LF, Del Aguila LF, et al. Expression of vascular endothelial growth factor by melanoma cells in